专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3567101A1 NATURAL KILLER CELL EXPRESSING ANTI-COTININE CHIMERIC ANTIGEN RECEPTOR 审中-公开
公开(公告)号：EP3567101A1
公开(公告)日：2019-11-13
申请号：EP18735838.7
申请日：2018-01-05
申请人： Korea Research Institute of Bioscience and Biotechnology , Seoul National University R & DB Foundation
发明人： CHOI, In Pyo , KIM, Tae-Don , LEE, Su Ui , LEE, Sooyun , CHUNG, Junho , KIM, Ki-Hyun
IPC分类号： C12N5/0783 , C12N15/115 , C07K16/44 , C07K14/705 , C07K14/725 , A61K35/17 , G01N33/569 , G01N33/574
摘要： The present invention relates to a natural killer cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent comprising same. The natural killer cell expressing a chimeric antigen receptor specifically binding to cotinine, according to the present invention, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell according to the present invention can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.

2. 发明公开

EP4375292A1 NOVEL CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS EXPRESSING SAME 审中-实审
公开(公告)号：EP4375292A1
公开(公告)日：2024-05-29
申请号：EP22846274.3
申请日：2022-07-21
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： KIM, Tae-Don , LEE, Sooyun
IPC分类号： C07K14/705 , C07K16/28 , C07K16/32 , A61P35/00 , A61K35/17
CPC分类号： C07K14/705 , C07K16/32 , C07K16/28 , A61P35/00 , A61K2239/2920230501 , A61K39/464406 , C12N5/0646 , A61K2239/2220230501 , A61K39/4646 , C12N5/0636 , A61K39/4613 , A61K39/4631 , A61K39/464404 , A61K39/464422
摘要： The present invention relates to: a novel chimeric antigen receptor containing, as an intracellular signaling domain, an intracellular domain of a receptor containing a dead region; and immune cells expressing the chimeric antigen receptor. In environments in which normal cells are present, the immune cells expressing the chimeric antigen receptor according to the present invention exhibit little or no cytotoxicity and cell death of the immune cells is exhibited, thus ensuring the stability of the normal cells. Conversely, in environments in which target cells are present, the immune cells exhibit more potent cytotoxicity than with conventional techniques utilizing a lone chimeric antigen receptor.

3. 发明授权

EP3252152B1 METHOD FOR MASS PRODUCING NATURAL KILLER CELL AND USE OF NATURAL KILLER CELL OBTAINED BY THE METHOD AS ANTI-CANCER AGENT 有权
公开(公告)号：EP3252152B1
公开(公告)日：2020-07-22
申请号：EP16743625.2
申请日：2016-01-15
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： CHOI, In Pyo , YOON, Suk Ran , LEE, Sooyun
IPC分类号： A61K35/17 , C12N5/0783 , A61P35/00 , A61P35/02 , A01N1/00

4. 发明公开

EP3252152A1 METHOD FOR MASS PRODUCING NATURAL KILLER CELL AND USE OF NATURAL KILLER CELL OBTAINED BY THE METHOD AS ANTI-CANCER AGENT 有权
标题翻译：用于批量生产天然杀伤细胞的方法和通过该方法获得的天然杀伤细胞作为抗癌剂的用途
公开(公告)号：EP3252152A1
公开(公告)日：2017-12-06
申请号：EP16743625.2
申请日：2016-01-15
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： CHOI, In Pyo , YOON, Suk Ran , LEE, Sooyun
IPC分类号： C12N5/0783 , A61K35/17 , A01N1/00 , A61P35/00
摘要： The present invention relates to a method for producing a large amount of natural killer cells and the use of natural killer cells obtained by the method as an anticancer agent. The use of the method of the present invention can produce fresh NK cells with high purity within a short time compared to conventional method, and can also produce cold-preserved NK cells and thawed cryopreserved NK cells, which have efficacy comparable with that of the fresh NK cells. Furthermore, it can produce NK cells, which have efficacy comparable with that of the fresh NK cells, from cryopreserved CD3-negative cells. The fresh NK cells, cold-preserved NK cells and cryopreserved NK cells produced by the methods of the present invention can exhibit therapeutic effects against various cancers, including colorectal cancer, lung cancer, liver cancer, pancreatic cancer and leukemia, indicating that these NK cells can be effectively used as cellular therapeutic agents. In addition, the present inventors have established doses and methods of administration, which show excellent effects when the fresh NK cells, cold-preserved NK cells and cryopreserved NK cells of the present invention are used as pharmaceutical compositions for cellular therapy.
摘要翻译：本发明涉及生产大量天然杀伤细胞的方法以及通过该方法获得的天然杀伤细胞作为抗癌剂的用途。与常规方法相比，使用本发明的方法可以在短时间内产生高纯度的新鲜NK细胞，并且还可以产生冷保存的NK细胞和解冻的冷冻保存的NK细胞，其具有与新鲜 NK细胞。此外，它可以从冷冻保存的CD3阴性细胞产生具有与新鲜NK细胞相当的效力的NK细胞。通过本发明的方法产生的新鲜NK细胞，冷保存的NK细胞和冷冻保存的NK细胞可表现出针对包括结直肠癌，肺癌，肝癌，胰腺癌和白血病的各种癌症的治疗效果，表明这些NK细胞可以有效地用作细胞治疗剂。另外，本发明人确定了将本发明的新鲜NK细胞，保存冷冻保存的NK细胞和冷冻保存的NK细胞作为细胞治疗用药物组合物使用时显示优异的效果的给药量和给药方法。

5. 发明公开

EP4332118A1 NOVEL ANTI-CD5 CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELL EXPRESSING SAME 审中-实审
公开(公告)号：EP4332118A1
公开(公告)日：2024-03-06
申请号：EP22796130.7
申请日：2022-04-27
申请人： Korea Research Institute of Bioscience and Biotechnology
发明人： KIM, Tae-Don , CHO, Seona , LEE, Sooyun
IPC分类号： C07K16/28 , C12N5/0783 , A61K35/17 , A61P35/00
摘要： The present invention relates to a CD5 antibody and a chimeric antigen receptor (CAR) including the same. The chimeric antigen receptor of the present invention may be expressed in an immune cell to be utilized for an immuno-oncology therapy having reduced toxicity against a normal T cell.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式